Summary
Background
Several recently proposed criteria for assessing cognitive disorder require measuring the cognitive domain of visuo-constructional function. The aims of the present study were to develop a new test (Vienna Visuo-constructional Test—VVT) measuring visuo-constructional functions and to determine the reliability and validity of the VVT in patients with mild cognitive impairment (MCI), Parkinson’s disease (PD), and Alzheimer’s disease (AD). We further examined age and sex effects and the psychometric quality of the VVT.
Methods
The study included 76 healthy controls and 103 patients who were referred to the Department of Neurology, Medical University of Vienna for neurocognitive assessment. An administering and scoring system for the VVT was developed.
Results
Internal consistency (Cronbach’s alpha) was found to range from 0.82 for the healthy control group to 0.93 for the total patient group. There was no sex effect, but age had a negative effect on VVT performance. The VVT successfully differentiated healthy controls from MCI patients, AD patients, and PD patients, respectively.
Conclusion
The VVT shows satisfactory validity and reliability and can be administered easily in clinical practice. It constitutes a new measure that can successfully be used to identify visuo-constructional problems in patients with cognitive dysfunction.
Zusammenfassung
Hintergrund
Mehrere kürzlich vorgeschlagenen Klassifikationsschemeta zur Beurteilung kognitiver Störung fordern die Erfassung der kognitiven Domäne „visuo-konstruktive Funktionen“. Das Ziel der vorliegenden Studie war die Entwicklung eines neuen Tests (Vienna Visuo-Constructional Test—VVT) zur Messung visuo-konstruktiver Funktionen. Mithilfe der VVT wurden bei Patienten mit leichter kognitiver Beeinträchtigung (MCI), Parkinson-Krankheit (PD) und Alzheimer (AD) die visuo-konstruktiven Fähigkeiten untersucht. Des Weiteren wurden Alters- und Geschlechtseffekte und die psychometrische Qualität des VVT bestimmt.
Methoden
Die Studie umfasste 76 gesunde Kontrollpersonen und 103 Patienten, die sich an der Universitätsklinik für Neurologie, Medizinische Universität Wien einer neurologischen Untersuchung unterzogen. Ein neuartiges Auswertungssystem für die VVT wurde entwickelt.
Ergebnisse
Die interne Konsistenz (Cronbach Alpha) lag im Bereich von 0,82 für die gesunde Kontrollgruppe und 0,93 für die gesamte Patientengruppe. Es zeigte sich kein Geschlechtereffekt, aber das Alter hatte einen negativen Effekt auf die VVT Leistung. Der VVT konnte erfolgreich zwischen gesunden Kontrollen und MCI-Patienten, Patienten mit AD und PD-Patienten differenzieren.
Schlussfolgerung
Der VVT zeigte eine zufriedenstellende Gültigkeit und Zuverlässigkeit und kann problemlos in der klinischen Praxis angewendet werden. Es stellt somit ein neues Verfahren dar, um visuell-konstruktive Probleme bei Patienten mit kognitiven Störungen zu identifizieren.
Similar content being viewed by others
References
Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9. doi:S1552-5260(11)00104-X [pii]10.1016/j.jalz.2011.03.008.
Litvan I, Goldman JG, Troester AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord. 2012;27(3):349–56. doi:10.1002/mds.24893.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. vol. DSM 5. Arlington: American Psychiatric Publishing; 2013.
Lezak MD. Neuropsychological assessment. New York: Oxford University Press; 1995.
Kleist K. Gehirnpathologie. Leipzig: Barth; 1934.
Foerster S, Teipel S, Zach C, Rominger A, Cumming P, la Fougere C, et al. FDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimers disease. J Psychiatric Res. 2010;44(7):462–9. doi:10.1016/j.jpsychires.2009.09.012.
Folstein M, Folstein S., McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Shulman KI. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry. 2000;15(6):548–61. doi:10.1002/1099-1166(200006)15:6<548::aid-gps242>3.3.co;2-l.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.
Rey A. The psychological examination in cases of traumatic encephalopathy. Arch Psychol. 1941;28:215–85.
Osterrieth PA. Test of copying a complex figure: contribution to the study of perception and memory. Arch Psychol. 1944;30:206–356.
Shon JM, Lee DY, Seo EH, Sohn BK, Kim JW, Park SY, et al. Functional neuroanatomical correlates of the executive clock drawing task (clox) performance in Alzheimer’s disease: a FDG-PET study. Neuroscience. 2013;246:271–80. doi:10.1016/j.neuroscience.2013.05.008.
Price CC, Cunningham H, Coronado N, Freedland A, Cosentino S, Penney DL, et al. Clock drawing in the montreal cognitive assessment: recommendations for dementia assessment. Dementia Geriatr Cogniti Disord. 2011;31(3):179–87. doi:10.1159/000324639.
Zec RF, Landreth ES, Vicari SK, Belman J, Feldman E, Andrise A, et al. Alzheimer-Disease Assessment Scale—a subtest analysis. Alzheimer Dis Assoc Disord. 1992;6(3):164–81. doi:10.1097/00002093-199206030-00004.
Lee H, Swanwick GR, Coen RF, Lawlor BA. Use of the clock drawing task in the diagnosis of mild and very mild Alzheimer’s disease. Int psychogeriatr/IPA. 1996;8(3):469–76. doi:10.1017/s1041610296002827.
Connor DJ, Seward JD, Bauer JA, Golden KS, Salmon DP. Performance of three clock scoring systems across different ranges of dementia severity. Alzheimer Dis Assoc Disord. 2005;19(3):119–27. doi:10.1097/01.wad.0000174948.77113.a6.
Sevigny JJ, Peng Y, Liu L, Lines CR. Item analysis of ADAS-Cog: effect of baseline cognitive impairment in a clinical AD trial. Am J Alzheimers Dis Other Dementias. 2010;25(2):119–24. doi:10.1177/1533317509350298.
Cormack F, Aarsland D, Ballard C, Tovee MJ. Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer’s disease, Parkinson’s disease and Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2004;19(4):371–7. doi:10.1002/gps.1094.
Pusswald G, Moser D, Gleiss A, Janzek-Hawlat S, Auff E, Dal-Bianco P, et al. Prevalence of mild cognitive impairment subtypes in patients attending a memory outpatient clinic-comparison of two modes of mild cognitive impairment classification. Results of the Vienna conversion to dementia study. Alzheimers Dementia. 2013;9(4):366–76. doi:10.1016/j.jalz.2011.12.009.
Lehrner J, Zach H, Moser D, Gleiss A, Auff E, Pirker W, et al. Prevalence of mild cognitive impairment subtypes in patients with Parkinson’s disease—comparison of two modes of classification. Zeitschrift für Neuropsychologie. 2014;25(1):49–63. doi:10.1024/1016-264X/a000116.
Lehrner J, Maly J, Gleiß A, Auff E, Dal-Bianco P. The Vienna Neuropsychological Test Battery (VNTB) for detecting dementia—standardization, norms, and validation. Psychologie in Österreich. 2007;4(5):358–65.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer disease. Neurology. 1984;34:939–44.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association; 2000.
Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinsons’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–52. doi:10.1136/jnnp.51.6.745.
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–94. doi:10.1111/j.1365-2796.2004.01388.xJIM1388 [pii].
Ivnik R, Malec JF, Smith GD, et.al. Mayo’s older Americans normative studies: WAIS-R, WMS-R and AVLT norms for ages 56 through 97. Clin Neuropsychol. 1992;6:1–104.
Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s disease assessment scale that broaden its scope. The Alzheimer’s disease cooperative study. Alzheimer Dis Assoc Disord. 1997;11 Suppl. 2:S13–21.
Libon DJ, Malamut BL, Swenson R, Sands LP, Cloud BS. Further analyses of clock drawings among demented and nondemented older subjects. Archives clin neuropsychol: the official J Nat Acad Neuropsychol. 1996;11(3):193–205. doi:10.1016/0887-6177(95)00026-7.
Acknowledgments
We would like to thank Sandra Kogler for proof reading the manuscript. A German version and an English version of the VVT are available free of charge from the authors.
Conflict of interest
Prof. Lehrner, Mag. Krakhofer, Prof. Lamm, Dr. Macher, Dr. Moser, Dr. Klug, Dr. Pusswald, Prof. Dal-Bianco, Prof. Pirker, and Prof. Auff report no disclosures.
Prof. Lehrner: Study concept and design, study supervision, acquisition of data, critical revision of the manuscript for important intellectual content.
Mag. Krakhofer: analysis and interpretation, drafting the manuscript
Prof. Lamm: critical revision of the manuscript for important intellectual content
Dr. Macher, Dr. Moser, and Mag. Klug: acquisition of data.
Prof. Dal-Bianco, Prof. Pirker, Prof. Auff, and Dr. Pusswald: critical revision of the manuscript for important intellectual content
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lehrner, J., Krakhofer, H., Lamm, C. et al. Visuo-constructional functions in patients with mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease. Neuropsychiatr 29, 112–119 (2015). https://doi.org/10.1007/s40211-015-0141-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40211-015-0141-2